Kusajili – Centralise les essais cliniques mondiaux

Extension Study for Long Term Evaluation of SAR153191 (REGN88) in Patients With Ankylosing Spondylitis Primary Objective: - To assess the long term safety of Sarilumab (SAR153191/REGN88) in patients with ankylosing spondylitis (AS) Secondary Objective: - To assess the long term efficacy of Sarilumab (SAR153191/REGN88) in patients with AS

• Pays Australia, Austria, Belgium, Canada, Czech Republic, France, Hungary, Lithuania, Netherlands, Poland, Spain, United States,
• Organes Aucun
• Spécialités Aucun

Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects The purpose of this study is to assess the safety and efficacy of brodalumab at two different doses compared with placebo in participants with moderate to severe plaque psoriasis. A second purpose of this study is to assess the safety and efficacy brodalumab at two different doses compared with ustekinumab in participants with moderate to severe plaque psoriasis. A third purpose of this study is to assess the safety and efficacy of 4 maintenance regimens of brodalumab.

• Pays Australia, Austria, Canada, Czech Republic, France, Hungary, Netherlands, Poland, Portugal, Spain, United States,
• Organes Aucun
• Spécialités Aucun

Follow on Study From RE-ALIGN To collect additional data relating to safety and indicators of efficacy for patients who have participated in the 1160.113 study.

• Pays Belgium, Canada, Czech Republic, Denmark, France, Germany, Netherlands, Norway, Poland,
• Organes Aucun
• Spécialités Aucun

Safety and Efficacy of SDX-101 (R-Etodolac) in Combination With Chlorambucil, and That of Chlorambucil Alone, in Patients With Chronic Lymphocytic Leukemia (CLL) This is a Phase 2, multi-center, open label, randomized clinical study to evaluate the safety and efficiency of SDX-101 in combination with chlorambucil (CLB) and chlorambucil alone in Chronic Lymphocytic Leukaemia (CLL) patients. The study treatment period will be approximately 24-26 weeks with a follow-up period of approximately 8 weeks. Following the end of treatment, patients with a confirmed complete response, partial response or stable disease will be followed for up to 2 years to assess time to disease progression. Approximately 80 patients with documented diagnosis of B-cell CLL by standard clinical and immunophenotyping criteria will be enrolled into the SDX-101-03 study. This study is being conducted in the following European countries: France, Germany, Poland, Sweden and the United Kingdom.

• Pays France, Germany, Poland, Sweden, United Kingdom,
• Organes Aucun
• Spécialités Aucun

Efficacy and Safety of Lu AA34893 in Patients With Bipolar Depression This study will evaluate the efficacy and safety of different doses of Lu AA34893 in the treatment of depression in patients with bipolar disorder.

• Pays Australia, Austria, Belgium, Bulgaria, Canada, France, Germany, Korea, Republic of, Lithuania, Malaysia, Philippines, Poland, Romania, Slovakia, Sweden, Taiwan, Province of China, Ukraine, United Kingdom,
• Organes Aucun
• Spécialités Aucun

Efficacy and Safety of SAR339658 in Patients With Moderate to Severe Ulcerative Colitis Primary Objective: To assess the efficacy of SAR339658 Secondary Objective: To assess the safety of SAR339658

• Pays Austria, Canada, France, Germany, Italy, Poland, United States,
• Organes Aucun
• Spécialités Aucun

Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects The purpose of this study is to assess the safety and efficacy of brodalumab at two different doses compared with placebo in participants with moderate to severe plaque psoriasis. A second purpose of this study is to assess the safety and efficacy brodalumab at two different doses compared with ustekinumab in participants with moderate to severe plaque psoriasis. A third purpose of this study is to assess the safety and efficacy of 4 maintenance regimens of brodalumab.

• Pays Australia, Belgium, Canada, France, Greece, Hungary, Italy, Latvia, Poland, Russian Federation, United States,
• Organes Aucun
• Spécialités Aucun

XL119 Versus 5-Fluorouracil (5-FU) Plus Leucovorin (LV) in Subjects With Advanced Biliary Tumors The main purpose of this study is to determine if XL119 is more effective than the combination of 5-fluorouracil (5FU) and leucovorin (LV) in prolonging the survival of subjects with advanced biliary tumors.

• Pays Belgium, Canada, France, Germany, Hungary, Italy, Poland, Russian Federation, Spain, United Kingdom, United States,
• Organes Aucun
• Spécialités Aucun

Safety and Efficacy Study to Evaluate the Effect of SLV320 on Renal Function in Patients With Worsening Heart Failure The purpose of this study is to determine the efficacy and safety of IV SLV320 in acute heart failure patients with renal dysfunction.

• Pays Canada, Chile, Denmark, France, Germany, Italy, Poland, Romania, Russian Federation, Ukraine, United States,
• Organes Aucun
• Spécialités Aucun

Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis To evaluate the efficacy and safety of AIN457 versus placebo in patients with relapsing multiple sclerosis.

• Pays Belgium, Czech Republic, France, Italy, Japan, Poland, Russian Federation, Spain, Sweden, Turkey,
• Organes Aucun
• Spécialités Aucun